These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21777277)

  • 1. CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D.
    Sheu BS; Cheng HC; Yeh YC; Chang WL
    J Gastroenterol Hepatol; 2012 Jan; 27(1):104-9. PubMed ID: 21777277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B.
    Chen WY; Chang WL; Tsai YC; Cheng HC; Lu CC; Sheu BS
    Am J Gastroenterol; 2010 May; 105(5):1046-52. PubMed ID: 19904250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole.
    Sheu BS; Chang WL; Cheng HC; Kao AW; Lu CC
    Am J Gastroenterol; 2008 Sep; 103(9):2209-14. PubMed ID: 18702650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes.
    Tseng PH; Lee YC; Chiu HM; Wang HP; Lin JT; Wu MS
    J Clin Gastroenterol; 2009; 43(10):920-5. PubMed ID: 19407662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
    Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
    Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
    Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
    J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
    Ariizumi K; Ohara S; Koike T; Inomata Y; Iijima K; Sekine H; Noguchi M; Sugiyama K; Eda Y; Kayaba S; Kawamura M; Shimosegawa T
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1428-34. PubMed ID: 16911688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
    Nagahara A; Suzuki T; Nagata N; Sugai N; Takeuchi Y; Sakurai K; Miyamoto M; Inoue K; Akiyama J; Mabe K; Konuma I; Kamada T; Haruma K
    J Gastroenterol; 2014 Dec; 49(12):1536-47. PubMed ID: 24366288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
    Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.
    Gawrońska-Szklarz B; Adamiak-Giera U; Wyska E; Kurzawski M; Gornik W; Kaldonska M; Drozdzik M
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1267-74. PubMed ID: 22418828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).
    Ward RM; Tammara B; Sullivan SE; Stewart DL; Rath N; Meng X; Maguire MK; Comer GM
    Eur J Clin Pharmacol; 2010 Jun; 66(6):555-61. PubMed ID: 20306184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism.
    Shao JG; Jiang W; Li KQ; Lu JR; Sun YY
    J Dig Dis; 2009 Feb; 10(1):55-60. PubMed ID: 19236548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial.
    Cho YK; Choi MG; Bak YT; Rhee PL; Kim SG; Jung HY; Seol SY
    Dig Dis Sci; 2012 Dec; 57(12):3189-94. PubMed ID: 22772870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease.
    Brunner G; Athmann C; Schneider A
    Aliment Pharmacol Ther; 2012 Jul; 36(1):37-47. PubMed ID: 22531114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
    Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
    Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
    Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
    Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.